The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | Varying efficacies of combination and monotherapies in CLL
Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, and Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, speaking at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. The speakers discuss a variety of novel therapies in chronic lymphocytic leukemia (CLL) treatment and compare the efficacies and limitations of these treatments in patients. The speakers also touch on the genetic screening of patients in order to better predict responses to treatment.
